The case involves a California woman who died from mesothelioma, a rare cancer. Her family claimed Johnson and Johnson’s talc powder products were to blame. By Kailyn Rhone A Los Angeles jury ordered ...

Johnson & Johnson was ordered to pay $966 million to the family of a woman who died from mesothelioma over allegations that its baby powder products caused the cancer. After Mae Moore died in 2021, ...

Johnson & Johnson is currently overvalued, with limited upside and mid-to-high single-digit long-term return potential amid ongoing sector risks. Despite solid recent earnings and raised guidance, JNJ ...

Today, Johnson & Johnson released its financial results for Q3 2025, which once again stunned Wall Street. So, sales of Rybrevant/Lazcluze, the 'diamond' in its oncology franchise, reached $198 ...

A Los Angeles jury ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, finding the company liable in the latest trial alleging its talc products cause ...

(Reuters) -A Los Angeles jury late on Monday ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, finding the company liable in the latest lawsuit ...

Health care giant Johnson & Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter ...

Oct 10 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab is in discussions to buy Protagonist Therapeutics (PTGX.O), opens new tab, a source familiar with the matter told Reuters. Shares of ...

Johnson & Johnson has been ordered to pay $966 million to the family of a California woman who died of mesothelioma. A Los Angeles jury found Johnson & Johnson liable for the 2021 death of Mae Moore, ...

A Los Angeles jury ordered Johnson & Johnson on Monday to pay $966 million to the family of a California woman who died from a rare and aggressive cancer, after the company was found liable in a ...

Johnson & Johnson said Tuesday it plans to separate its artificial hip and knee business into a stand-alone company to be called DePuy Synthes—the latest attempt to slim down by the healthcare giant.